Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. Variation in population size of the donor strain HN-1 and E

Published byOnur Nabi Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 1. Variation in population size of the donor strain HN-1 and E"— Presentation transcript:

1 Figure 1. Variation in population size of the donor strain HN-1 and E
Figure 1. Variation in population size of the donor strain HN-1 and E. coli transconjugants that had acquired the ... Figure 1. Variation in population size of the donor strain HN-1 and E. coli transconjugants that had acquired the bla<sub>NDM-1</sub>-bearing plasmid during a 16 day treatment period. For E. coli, only at day 4 and day 13 was a significant difference (P < 0.0001) observed among different treatment groups. For HN-1, significant differences (P = 0.03 to <0.0001) were observed among different treatment groups at all timepoints but not day 16. For transconjugants (TC), significant differences (P = 0.008 to <0.0001) were observed among different treatment groups at all timepoints. One-way ANOVA was used for the analysis. AMC, amoxicillin/clavulanate; AMP, ampicillin; CTX, cefotaxime; MEM, meropenem; DAP, daptomycin. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( J Antimicrob Chemother, dkz137, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 2. Composition of faecal microbial communities at the phylum level recorded at days 0, 4, 7 and 16 during ... Figure 2. Composition of faecal microbial communities at the phylum level recorded at days 0, 4, 7 and 16 during treatment with different antibiotics. HN-1 depicts inoculation with the strain HN-1 without antimicrobial treatment. For Bacteroidetes, Firmicutes, Proteobacteria and other phyla, significant differences (P = 0.003 to <0.0001) were observed among different treatment groups at all timepoints. One-way ANOVA was used for the analysis. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( J Antimicrob Chemother, dkz137, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Figure 3. Variation in composition of Proteobacteria at the genus level upon infection of strain HN-1 and treatment ... Figure 3. Variation in composition of Proteobacteria at the genus level upon infection of strain HN-1 and treatment with different antibiotics, with Escherichia–Shigella and Klebsiella as marker strains. For E. coli, significant differences (P = 0.023) among different treatment groups were observed only at day 7. For HN-1, significant differences among different treatment groups were observed at day 0 (P = 0.044), day 4 (P < 0.0001) and day 7 (P < 0.0001). For other Proteobacteria, significant differences among different treatment groups were observed only at day 0 (P = 0.043) and day 4 (P = 0.042). One-way ANOVA was used for the analysis. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( J Antimicrob Chemother, dkz137, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1. Variation in population size of the donor strain HN-1 and E"

Similar presentations

Figure 1. Ten chemotherapeutic drugs induce the bacterial SOS response

Figure 1. Ten chemotherapeutic drugs induce the bacterial SOS response
Figure 1. Direct evidence for the acquisition and demise of Tn6330 by DNA sequence alignment. (a) Comparison between ... Figure 1. Direct evidence for.

Figure 1. Direct evidence for the acquisition and demise of Tn6330 by DNA sequence alignment. (a) Comparison between ... Figure 1. Direct evidence for.
Figure 1. Comparative chromosome map of the CP-hvKP strain (NUHL30457) and 10 other hvKP strains (1158, CG43, HK787, ... Figure 1. Comparative chromosome.

Figure 1. Comparative chromosome map of the CP-hvKP strain (NUHL30457) and 10 other hvKP strains (1158, CG43, HK787, ... Figure 1. Comparative chromosome.
Figure 1. Distribution of ABCB1 SNVs and haplotypes.

Figure 1. Distribution of ABCB1 SNVs and haplotypes.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 Data-selection process

Figure 1 Data-selection process
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
Figure 1. Colistin MIC distribution for the 153 colistin-resistant E

Figure 1. Colistin MIC distribution for the 153 colistin-resistant E
Figure 1 Phases of the research. Author’s own work.

Figure 1 Phases of the research. Author’s own work.
Figure 1. Structure of resistance islands containing dfrA35 in IncC plasmids. (a) pEc158 resistance island and (b) ... Figure 1. Structure of resistance.

Figure 1. Structure of resistance islands containing dfrA35 in IncC plasmids. (a) pEc158 resistance island and (b) ... Figure 1. Structure of resistance.
Figure 1. Linkage analyses of the SNPs in the MRE11 gene and haplotype blocks. Haplotype blocks were defined for all ... Figure 1. Linkage analyses of.

Figure 1. Linkage analyses of the SNPs in the MRE11 gene and haplotype blocks. Haplotype blocks were defined for all ... Figure 1. Linkage analyses of.
Figure 1. Structure of two poxtA-carrying plasmids in E

Figure 1. Structure of two poxtA-carrying plasmids in E
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1. Physician rankings from 0 to 100 in the odds of prescribing an antibiotic. The y-axis represents the null ... Figure 1. Physician rankings from.

Figure 1. Physician rankings from 0 to 100 in the odds of prescribing an antibiotic. The y-axis represents the null ... Figure 1. Physician rankings from.
Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.
AHA: American Heart Association; ALT: ...

AHA: American Heart Association; ALT: ...
Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.
Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.
Fig. 1 CT demonstrating aortic wall thickening with renal artery involvement (short arrow). There is also subtle ... Fig. 1 CT demonstrating aortic wall.

Fig. 1 CT demonstrating aortic wall thickening with renal artery involvement (short arrow). There is also subtle ... Fig. 1 CT demonstrating aortic wall.

Similar presentations

Ads by Google